Aytu BioPharma (NASDAQ:AYTU – Get Free Report) was downgraded by analysts at Maxim Group from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday, Benzinga reports.
AYTU has been the topic of a number of other research reports. Lake Street Capital lowered shares of Aytu BioPharma from a “buy” rating to a “hold” rating and set a $2.70 price objective on the stock. in a research report on Tuesday. Zacks Research downgraded shares of Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Citigroup reaffirmed a “positive” rating on shares of Aytu BioPharma in a research report on Tuesday, September 22nd. Finally, Weiss Ratings lowered shares of Aytu BioPharma from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, October 6th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $8.60.
Get Our Latest Stock Report on AYTU
Aytu BioPharma Stock Up 45.9%
NASDAQ AYTU traded up $0.83 during trading on Tuesday, hitting $2.65. The stock had a trading volume of 3,241,567 shares, compared to its average volume of 67,273. The company has a market capitalization of $28.85 million, a PE ratio of -1.60 and a beta of 0.24. The company’s 50-day moving average price is $2.01 and its two-hundred day moving average price is $2.27. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.00 and a current ratio of 1.13. Aytu BioPharma has a 12 month low of $1.75 and a 12 month high of $3.06.
Aytu BioPharma (NASDAQ:AYTU – Get Free Report) last issued its quarterly earnings results on Monday, November 16th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.06. The company had revenue of $14.84 million during the quarter, compared to analysts’ expectations of $13.27 million. Aytu BioPharma had a negative net margin of 24.76% and a negative return on equity of 56.54%. As a group, sell-side analysts forecast that Aytu BioPharma will post -0.16 EPS for the current year.
Institutional Investors Weigh In On Aytu BioPharma
Several large investors have recently made changes to their positions in AYTU. Stonepine Capital Management LLC bought a new stake in Aytu BioPharma during the second quarter worth $1,962,780. AWM Investment Company Inc. acquired a new stake in Aytu BioPharma in the second quarter valued at $1,332,000. Nantahala Capital Management LLC acquired a new stake in Aytu BioPharma in the second quarter valued at $2,336,646. BlackRock Inc. acquired a new stake in Aytu BioPharma in the second quarter valued at $49,000. Finally, Crown Advisors Management Inc. bought a new position in shares of Aytu BioPharma in the 2nd quarter valued at about $430,000. Institutional investors and hedge funds own 33.49% of the company’s stock.
Aytu BioPharma News Roundup
These are some of the AYTU news items that stood out recently:
- Positive Sentiment: Rosemont has agreed to acquire Aytu for $2.70 per share in cash. The deal news is the primary catalyst behind the stock’s move, though completion remains subject to the transaction’s terms. Rosemont acquisition announcement
- Positive Sentiment: Fiscal 2027 first-quarter revenue was $14.84 million, above analysts’ expectations of $13.27 million. The reported loss of $0.20 per share was also narrower than the $0.26 loss estimate cited in some reports. Quarterly results and acquisition
- Negative Sentiment: The company remained loss-making, with a $0.20-per-share quarterly loss versus $0.08 a year earlier; reports attributed the loss to higher costs. Aytu reports first-quarter loss
Aytu BioPharma Company Profile
Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing prescription treatments. Its business has centered on medicines for attention-deficit/hyperactivity disorder (ADHD) and other pediatric conditions. The company’s product portfolio has included ADHD medications such as Adzenys XR-ODT, an orally disintegrating amphetamine tablet, and Cotempla XR-ODT, an extended-release methylphenidate tablet. Aytu has also marketed treatments for other pediatric needs, including allergies.
See Also
- Five stocks we like better than Aytu BioPharma
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
